← Eichor
Condition: Extrahepatic Cholangiocarcinoma And Gallbladder Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Extrahepatic Cholangiocarcinoma And Gallbladder Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07614061
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing So
Phase 1 · 7 location(s) · Myeloid Therapeutics · NCT07334119
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-posi
Phase 3 · 185 location(s) · Jazz Pharmaceuticals · NCT06282575
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07641036
Bile Omics for Diagnosing Indeterminate Biliary Strictures
Phase N/A · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07007832
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
NA · 1 location(s) · University of California, Davis · NCT06101277
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
Phase N/A · 1 location(s) · Yingbin Liu, MD, PhD, FACS · NCT07176962
Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Ca
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07636824
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metast
Phase 2 · 1 location(s) · Yale University · NCT07282912
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Ph
Phase 3 · 18 location(s) · J-Pharma Co., Ltd. · NCT07265674
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.